ZOMETA Dosing and Administration

For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.

Advanced Solid Tumours and Multiple
Myeloma

This is an international site for Zometa^® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Zometa Information for US residents Zometa Information for Patients Outside the US

Welcome to the ZOMETA Product Website

ZOMETA is approved for use in
95 countries
around the world.

ZOMETA Country-Level Websites

Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.

ZOMETA International Website

This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus .

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Text size:

Treat with ZOMETA every 3 to 4 weeks in multiple myeloma and advanced solid tumours¹

Recommended ZOMETA dosing optimises treatment in advanced cancers^1,2

ZOMETA 4 mg in 100 mL of calcium-free infusion solution should be infused over no less than 15 minutes¹
- Patients with mild to moderate renal impairment should be administered a reduced dose
- ZOMETA is not recommended for patients with severe renal impairment
Patients should be adequately hydrated before receiving ZOMETA^1,3

Learn about guidelines to protect patients’ renal health.

Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily¹

References: 1. ZOMETA Summary of Product Characteristics. Novartis Pharma AG. 2. Hatoum HT, Lin S-J, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008;113:1438-1445. 3. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10:52-62. 4. Data on file. Novartis Pharma AG.

Advanced Solid Tumours and Multiple Myeloma